Welcome to our dedicated page for Nutriband news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Overview of Nutriband Inc.
Nutriband Inc. (NASDAQ: NTRB, NASDAQ: NTRBW) is a U.S.-based pharmaceutical company headquartered in Oviedo, Florida. The company specializes in the development of innovative transdermal drug delivery systems, with a primary focus on addressing the global opioid crisis through its proprietary AVERSA™ abuse-deterrent technology. This technology is designed to incorporate aversive agents into transdermal patches to prevent the abuse, misuse, diversion, and accidental exposure of drugs with high abuse potential, such as opioids.
Core Technology: AVERSA™
The cornerstone of Nutriband’s operations is its patented AVERSA™ technology, which employs a proprietary aversive agent coating to deter oral abuse and accidental exposure. This innovation is particularly significant for transdermal drugs like fentanyl, which carry a high risk of misuse. The AVERSA™ platform has broad applications and can be integrated into various transdermal patches, enhancing the safety profile of essential medications while ensuring accessibility for patients in need.
Key Product: AVERSA™ Fentanyl
The company’s lead product under development is AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system. This product aims to be the world’s first abuse-deterrent opioid patch, addressing the dual challenges of opioid misuse and accidental exposure. AVERSA™ Fentanyl is being developed in collaboration with Kindeva Drug Delivery, a leading global contract development and manufacturing organization. The product is advancing through the U.S. FDA’s streamlined 505(b)(2) NDA regulatory pathway, which requires minimal clinical trials, potentially accelerating its time to market.
Intellectual Property and Global Reach
Nutriband’s AVERSA™ technology is protected by an extensive international intellectual property portfolio, with patents issued in 46 countries, including the United States, Europe, Japan, Korea, Russia, China, Canada, and Australia. This robust patent coverage positions the company to commercialize its technology on a global scale, ensuring competitive advantages in major pharmaceutical markets.
Revenue Streams and Market Presence
In addition to its pharmaceutical innovations, Nutriband generates revenue through its wholly-owned subsidiary, Pocono Pharma, which offers contract manufacturing services. The subsidiary specializes in kinesiology tape and other consumer transdermal products, supplying major retail chains such as Target, Walmart, Walgreens, and CVS. This diversified revenue model strengthens the company’s financial foundation while supporting its core R&D initiatives.
Strategic Collaborations
Nutriband has established strategic partnerships to advance its product pipeline. Its collaboration with Kindeva Drug Delivery ensures the scalability and commercial manufacturing capabilities required for AVERSA™ Fentanyl. Additionally, the company has licensed the use of Bitrex®, the world’s most bitter substance, as an aversive agent in its abuse-deterrent patches, further enhancing the effectiveness of its technology.
Market Significance
By addressing critical issues such as opioid misuse and accidental exposure, Nutriband positions itself as a key player in the abuse-deterrent pharmaceutical segment. The global market for such technologies is growing, driven by increasing regulatory focus on opioid safety and the need for innovative solutions to combat the opioid crisis. Nutriband’s AVERSA™ technology not only meets these demands but also sets a new standard for safety in transdermal drug delivery.
Conclusion
Nutriband Inc. is at the forefront of pharmaceutical innovation, leveraging its AVERSA™ technology to enhance patient safety and address pressing public health challenges. With its strong intellectual property portfolio, strategic collaborations, and diversified revenue streams, the company is well-positioned to make a significant impact in the pharmaceutical industry, particularly in the realm of abuse-deterrent drug delivery systems.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has entered into an exclusive manufacturing agreement with Fleur Marché for CBD and Botanical Patches. Nutriband's subsidiary, Active Intelligence, will be the exclusive manufacturer for these products. Fleur Marché, founded in 2019, focuses on wellness patches aimed at simplifying health solutions for busy consumers. Products are available in retailers such as Bed Bath and Beyond and Nordstrom. This partnership is expected to highlight Nutriband's manufacturing capabilities using innovative technologies.
Nutriband Inc. (NASDAQ:NTRB) announced its subsidiary, 4P Therapeutics, completed a Phase 1b clinical study for Sorrento Therapeutics (NASDAQ:SRNE). Results will be presented at the American College of Rheumatology (ACR) Convergence 2022 on November 13, 2022, highlighting significant improvements in rheumatoid arthritis disease measures at 50% of the standard dose. The study emphasizes the potential of the Sofusa lymphatic delivery platform for treating autoimmune diseases and showcases 4P Therapeutics' capabilities in advancing drug delivery products.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has been invited to speak at the 2023 Transdermal and Microneedle Conference in London on January 23-24. CEO Gareth Sheridan will present on improving transdermal technologies to reduce the abuse potential of medications, referencing their AVERSA technology. Additionally, COO Dr. Alan Smith will participate in a panel discussion on microneedles as a drug delivery tool. Other notable participants include representatives from Merck, GSK, and Sanofi.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced progress in collaboration with Kindeva Drug Delivery for their AVERSA™ Fentanyl patch, an abuse-deterrent transdermal system. Recent studies confirm that Nutriband's aversive coating can be produced with standard manufacturing processes, crucial for product development. The product has a projected peak annual sales potential of $80M - $200M within five years post-launch. Nutriband aims to finalize product configuration and transfer technology to Kindeva's commercial facility in California.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has initiated the application process for a dual listing on Upstream, a digital trading app. This move aims to tap into a global investor base, facilitating trades in USDC digital currency and traditional payment methods. CEO Gareth Sheridan emphasized that this listing could enhance shareholder value and liquidity while expanding access to international markets. Approval from MERJ Exchange is pending; however, Nutriband's adherence to NASDAQ standards is sufficient for compliance. The company is known for developing abuse deterrent technologies for pharmaceuticals.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) will be featured on the RedChip Money Report airing on Bloomberg TV this Saturday, September 17, at 7 p.m. ET. The interview will highlight various aspects of the company, including expanded patents, commercialization plans, and Q2 revenue results. Chairman & President Serguei Melnik will discuss these developments, which could pique investor interest. Bloomberg TV reaches approximately 73 million homes across the U.S.
Nutriband Inc. (NASDAQ:NTRB) reported significant growth in its Q2 2022 financial results, achieving record quarterly revenue of $0.5 million, a 113% increase year-over-year. Over six months, revenue rose 44%. The company received a favorable court ruling enabling the cancellation of 1.2 million shares, representing 15% of outstanding shares at the time. Nutriband continues to expand its AVERSA™ intellectual property, now protected in 45 countries. However, net loss increased to $1.0 million from $0.5 million year-over-year.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced the effective date of a 7:6 forward stock split that took place on August 12, 2022, with a record date of August 15, 2022. Each holder of 6 shares of common stock received 7 shares, with no change to the per-share par value. The stock split will not affect stockholders' equity percentages. Additionally, the exercise price of outstanding warrants will be adjusted to $6.43 per share, corresponding to the stock split ratio. Book-entry holders do not need to take action, while those seeking stock certificates will receive further instructions.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced the receipt of a Notice of Allowance for its patent application from the Canadian Intellectual Property Office. This patent is crucial for the company's AVERSA™ transdermal abuse deterrent technology, enhancing intellectual property protection across North America.
The AVERSA™ technology aims to reduce drug misuse and abuse while ensuring accessibility for patients in need. The lead product, AVERSA™ Fentanyl, is projected to achieve peak annual sales of $80M - $200M. Nutriband's patent portfolio spans multiple countries, bolstering its market position.
Nutriband Inc. (NTRB, NTRBW) announced a 7:6 forward stock split effective at 12:01 AM on August 15, 2022. Shareholders will receive seven shares for every six shares held, maintaining the par value. CEO Gareth Sheridan emphasized the company's commitment to creating shareholder value following recent milestones. Nutriband is focused on developing transdermal pharmaceutical products, notably an abuse deterrent fentanyl patch utilizing its AVERSA technology. The company acknowledges various risks involved in its development and regulatory processes.
FAQ
What is the current stock price of Nutriband (NTRBW)?
What does Nutriband Inc. specialize in?
What is AVERSA™ technology?
What is Nutriband’s lead product?
Where is Nutriband’s technology patented?
How does Nutriband generate revenue?
Who are Nutriband’s strategic partners?
What challenges does Nutriband face?
What makes Nutriband unique in the pharmaceutical industry?
